Company intelligence / Profile preview

KeyVac

Ankara, Ankara, Turkey

Ownership: Private
Development stage: Other

Overview

The company operates a GMP-certified plant capable of producing 30 million vaccine doses per year, currently commercializing inactivated hepatitis A vaccines and preparing to add varicella and influenza vaccines for local and regional supply[1][2][4].

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

Sinovac BiotechAlagöz Holding

Beyond the preview

Go deeper on KeyVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeyVac.

Explore the full profile